C-T Huang1, Y-J Tsai, J-Y Fan, S-C Ku, C-J Yu. 1. Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Br., Yunlin, Taiwan.
Abstract
BACKGROUND: The human immunodeficiency virus (HIV) epidemic and increasing use of immunosuppressive agents have increased the prevalence of both cryptococcosis and tuberculosis (TB). However, the status of co-infection with both pathogens remains unknown. METHODS: This study retrospectively reviewed patient records of cryptococcosis and TB co-infection from 1993 to 2006. The temporal sequence of co-infection was defined as either concurrent or sequential. Data collected included patient demographics, HIV status, co-morbidities, clinical manifestations, treatment strategies, and outcome at 1-year follow-up. RESULTS: There were 23 patients with cryptococcosis and TB co-infection, representing 5.4% of cryptococcosis or 0.6% of TB cases. Eleven (48%) patients were HIV-infected, and no underlying disease or immunocompromised state could be identified in six (26%) patients. Twelve (52%) patients presented with concurrent infection, but diagnosis of co-infection could be achieved simultaneously in only three (13%). Constitutional symptoms, particularly fever and weight loss, were the most common presenting symptoms, developing in more than two-thirds of the patients. The majority (83%) of the patients made a good recovery following dual antifungal and anti-TB therapy. There were three mortalities at the 1-year follow-up, which might be attributable to a delay in diagnosis and treatment of co-infection. The outcomes of HIV-infected and non-HIV-infected patients were not significantly different. CONCLUSIONS: Cryptococcosis and TB co-infection, although rare, develops in both immunocompromised and healthy individuals. Early diagnosis and treatment may improve patient prognosis. There should be a high index of suspicion in order to achieve a timely diagnosis in a TB endemic area.
BACKGROUND: The human immunodeficiency virus (HIV) epidemic and increasing use of immunosuppressive agents have increased the prevalence of both cryptococcosis and tuberculosis (TB). However, the status of co-infection with both pathogens remains unknown. METHODS: This study retrospectively reviewed patient records of cryptococcosis and TB co-infection from 1993 to 2006. The temporal sequence of co-infection was defined as either concurrent or sequential. Data collected included patient demographics, HIV status, co-morbidities, clinical manifestations, treatment strategies, and outcome at 1-year follow-up. RESULTS: There were 23 patients with cryptococcosis and TB co-infection, representing 5.4% of cryptococcosis or 0.6% of TB cases. Eleven (48%) patients were HIV-infected, and no underlying disease or immunocompromised state could be identified in six (26%) patients. Twelve (52%) patients presented with concurrent infection, but diagnosis of co-infection could be achieved simultaneously in only three (13%). Constitutional symptoms, particularly fever and weight loss, were the most common presenting symptoms, developing in more than two-thirds of the patients. The majority (83%) of the patients made a good recovery following dual antifungal and anti-TB therapy. There were three mortalities at the 1-year follow-up, which might be attributable to a delay in diagnosis and treatment of co-infection. The outcomes of HIV-infected and non-HIV-infectedpatients were not significantly different. CONCLUSIONS:Cryptococcosis and TB co-infection, although rare, develops in both immunocompromised and healthy individuals. Early diagnosis and treatment may improve patient prognosis. There should be a high index of suspicion in order to achieve a timely diagnosis in a TB endemic area.
Authors: R S Heyderman; I T Gangaidzo; J G Hakim; J Mielke; A Taziwa; P Musvaire; V J Robertson; P R Mason Journal: Clin Infect Dis Date: 1998-02 Impact factor: 9.079
Authors: Payam Nahid; Leah C Gonzalez; Irina Rudoy; Bouke C de Jong; Alon Unger; L Masae Kawamura; Dennis H Osmond; Philip C Hopewell; Charles L Daley Journal: Am J Respir Crit Care Med Date: 2007-02-08 Impact factor: 21.405
Authors: J L Flynn; M M Goldstein; J Chan; K J Triebold; K Pfeffer; C J Lowenstein; R Schreiber; T W Mak; B R Bloom Journal: Immunity Date: 1995-06 Impact factor: 31.745
Authors: Lidya Chaidir; Ahmad Rizal Ganiem; Adri Vander Zanden; Soni Muhsinin; Tina Kusumaningrum; Inri Kusumadewi; Andre van der Ven; Bachti Alisjahbana; Ida Parwati; Reinout van Crevel Journal: PLoS One Date: 2012-12-21 Impact factor: 3.240
Authors: Jayne Ellis; Fiona V Cresswell; Joshua Rhein; Kenneth Ssebambulidde; David R Boulware Journal: Open Forum Infect Dis Date: 2018-08-29 Impact factor: 3.835
Authors: Morris K Rutakingirwa; Fiona V Cresswell; Richard Kwizera; Kenneth Ssebambulidde; Enock Kagimu; Edwin Nuwagira; Lillian Tugume; Edward Mpoza; Joanna Dobbin; Darlisha A Williams; Conrad Muzoora; David B Meya; David R Boulware; Kathy H Hullsiek; Joshua Rhein Journal: J Clin Med Date: 2020-03-13 Impact factor: 4.241